512 Stock Overview
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Grand Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$8.69 |
| 52 Week High | HK$9.00 |
| 52 Week Low | HK$4.04 |
| Beta | 0.75 |
| 1 Month Change | 47.54% |
| 3 Month Change | 81.04% |
| 1 Year Change | 80.67% |
| 3 Year Change | 109.40% |
| 5 Year Change | 68.09% |
| Change since IPO | -66.58% |
Recent News & Updates
Recent updates
Grand Pharmaceutical Group Limited (HKG:512) Stock Rockets 41% As Investors Are Less Pessimistic Than Expected
May 12
Grand Pharmaceutical Group Limited's (HKG:512) CEO Compensation Looks Acceptable To Us And Here's Why
Apr 03Additional Considerations Required While Assessing Grand Pharmaceutical Group's (HKG:512) Strong Earnings
Mar 25Little Excitement Around Grand Pharmaceutical Group Limited's (HKG:512) Earnings
Feb 24Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 19Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year
Jun 05Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings
May 22Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Apr 25Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Mar 25We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt
Oct 20Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Sep 26Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14
Jun 04Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?
May 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Nov 21Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?
Sep 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Aug 16Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Jul 28Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11
May 29Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?
Apr 08Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet
Mar 22Shareholder Returns
| 512 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 6.1% | 10.1% | 1.4% |
| 1Y | 80.7% | 22.3% | 15.4% |
Return vs Industry: 512 exceeded the Hong Kong Pharmaceuticals industry which returned 20.4% over the past year.
Return vs Market: 512 exceeded the Hong Kong Market which returned 14.8% over the past year.
Price Volatility
| 512 volatility | |
|---|---|
| 512 Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in HK Market | 15.2% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 512 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 512's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 11,987 | Chao Zhou | www.grandpharm.com |
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products.
Grand Pharmaceutical Group Limited Fundamentals Summary
| 512 fundamental statistics | |
|---|---|
| Market cap | HK$30.43b |
| Earnings (TTM) | HK$2.47b |
| Revenue (TTM) | HK$11.64b |
Is 512 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 512 income statement (TTM) | |
|---|---|
| Revenue | HK$11.64b |
| Cost of Revenue | HK$4.91b |
| Gross Profit | HK$6.74b |
| Other Expenses | HK$4.27b |
| Earnings | HK$2.47b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.70 |
| Gross Margin | 57.87% |
| Net Profit Margin | 21.20% |
| Debt/Equity Ratio | 26.5% |
How did 512 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 06:16 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Grand Pharmaceutical Group Limited is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yanyin Zhu | China International Capital Corporation Limited |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Chao Zhang | Guosen Securities Co., Ltd. |